The Tailored Biosimilar Approach: Expectations and Requirements.

Area of Science:

• Biopharmaceutical Science
• Regulatory Science
• Drug Development

Background:

• Current biosimilar approval relies on physicochemical, functional, pharmacokinetic data, and clinical efficacy studies (CES).
• Regulatory thinking is evolving towards a tailored biosimilar approach, minimizing reliance on CES.
• Limitations exist in using CES for definitive regulatory decision-making in biosimilarity.

Purpose of the Study:

• To discuss the tailored biosimilar approach as an evolution in regulatory strategy.
• To explore the predictive value of physicochemical and functional data for clinical performance.
• To outline future requirements and exceptions for biosimilar approvals.

Main Methods:

• Review of current regulatory requirements for biosimilar approval.
• Analysis of physicochemical and functional testing as predictors of clinical outcomes.
• Examination of pharmacokinetic study designs for biosimilarity assessment.
• Identification of specific scenarios necessitating additional clinical evidence.

Main Results:

• Physicochemical and functional data, combined with pharmacokinetic studies, can sufficiently establish biosimilarity in most cases.
• The tailored approach can streamline biosimilar development and regulatory review.
• CES may not always be necessary, depending on product characterization and known risks.

Conclusions:

• The tailored biosimilar approach represents a significant advancement in regulatory science.
• Robust analytical data can often replace extensive clinical trials for biosimilar approval.
• Specific exceptions exist where additional clinical data remain essential for ensuring patient safety and product efficacy.